Patents Represented by Attorney, Agent or Law Firm Shelley P. Eberle
  • Patent number: 6835392
    Abstract: A permeation enhancer composition is provided for increasing the permeability of skin or mucosal tissue to topically or transdermally administered pharmacologically or cosmeceutically active agents. The composition is comprised of a hydroxide-releasing agent and a lipophilic co-enhancer such as a fatty alcohol, a fatty ether, or a fatty acid ester, including fatty acid esters of polyols such as propylene glycol and glycerol. Also provided are pharmaceutical formulations containing a therapeutically effective amount of an active agent in addition to the aforementioned enhancer composition, methods for administering active agents topically or transdermally with enhanced permeation, and drug delivery systems for application to an individual's skin or mucosal tissue, wherein the systems are formulated so as to contain an active agent to be administered and an effective permeation enhancing amount of an enhancer composition of the invention.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: December 28, 2004
    Assignee: Dermatrends, Inc.
    Inventors: Tsung-Min Hsu, Eric C. Jacobson, Rose C. LoBello, Eric C. Luo
  • Patent number: 6821523
    Abstract: Provided are methods and topical pharmaceutical formulations for use in the treatment of warts. The invention involves the topical administration of a pharmacologically active base in a formulation having a pH of about 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations can be used to treat human papilloma virus infections, particularly cutaneous warts.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: November 23, 2004
    Assignee: Dermatrends, Inc.
    Inventors: Howard I. Maibach, Eric C. Luo, Tsung-Min Hsu
  • Patent number: 6815064
    Abstract: Methods for synthesizing luminescent nanoparticles and nanoparticles prepared by such methods are provided. The nanoparticles are prepared by a method in which an additive is included in the reaction mixture. The additive may be a Group 2 element, a Group 12 element, a Group 13 element, a Group 14 element, a Group 15 clement, or a Group 16 element. In additions, a luminescent nanoparticle is provided that comprises a semiconductive core surrounded by an inorganic shell, an interfacial region and an additive present in the interfacial region or both the interfacial region and the shell.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: November 9, 2004
    Assignee: Quantum Dot Corporation
    Inventors: Joseph A. Treadway, Donald A. Zehnder, Marc D. Schrier
  • Patent number: 6803420
    Abstract: An adhesive composition is provided that contains both a hydrophobic phase and a hydrophilic phase, wherein the hydrophobic phase is composed of a crosslinked hydrophobic polymer composition and the hydrophilic phase is a water-absorbent blend of a hydrophilic polymer and a complementary oligomer capable of crosslinking the hydrophilic polymer through hydrogen bonding, ionic bonding, and/or covalent bonding. The composition is useful as a bioadhesive, for affixing drug delivery systems, wound dressings, bandages, cushions, or the like to a body surface such as skin or mucosal tissue.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: October 12, 2004
    Assignees: Corium International, A.V. Topchiev Institute of Petrochemical Synthsis, Russian Academy of Sciences
    Inventors: Gary W. Cleary, Mikhail M. Feldstein, Valery G. Kulichikhin, Danir F. Bairamov
  • Patent number: 6737504
    Abstract: A method for preparing a wide range of substituted poly(aniline)s from a single precursor is described. The method uses a variety of reactions, including a boron activation/electrophilic displacement reaction resulting in ipso-substitution. The ability to tune the properties of poly(aniline) through the generation of new structures is useful in numerous fields ranging from polymer-based electronics to sensors.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: May 18, 2004
    Assignee: California Institute of Technology
    Inventors: Michael S. Freund, Eiichi Shoji
  • Patent number: 6719997
    Abstract: Methods, compositions and drug delivery systems are provided for the transdermal administration of a pharmacologically active amine. The active agent is administered with a hydroxide-releasing agent that serves as a permeation enhancer. Exemplary hydroxide-releasing agents are inorganic hydroxides, inorganic oxides, and alkali metal or alkaline earth metal salts of weak acids. Inorganic hydroxides include, for example, ammonium hydroxide, alkali metal hydroxides and alkaline earth metal hydroxides, such as sodium hydroxide, calcium hydroxide, potassium hydroxide, magnesium hydroxide, and the like.
    Type: Grant
    Filed: December 14, 2000
    Date of Patent: April 13, 2004
    Assignee: Dermatrends, Inc.
    Inventors: Tsung-Min Hsu, Russell Macy, Eric C. Luo
  • Patent number: 6693187
    Abstract: Phosphinoamidite carboxylates and analogs are provided that have the structure of formula (I) wherein R1, R2, R3, R4, X, Y, Z and n are as defined herein. The compounds are useful as phosphitylating agents, e.g., in the phosphitylation of 3′ and 5′ hydroxyl groups of nucleosides and oligonucleotides. Also provided are phosphonocarboxylate and H-phosphonite carboxylate analogs of the compounds of formula (I). The compounds enable synthesis of phosphinocarboxylate and phosphonocarboxylate oligonucleotides having reduced internucleotide charge and enhanced nuclease resistance.
    Type: Grant
    Filed: October 17, 2000
    Date of Patent: February 17, 2004
    Assignee: Lievre Cornu LLC
    Inventor: Douglas J. Dellinger
  • Patent number: 6686132
    Abstract: A method for enhancing resist sensitivity and resolution based on influencing the effects of photoacid drift and diffusion by an externally applied electric field that may optionally include a direct current offset bias is disclosed. An electric field applied to the resist film during post exposure bake (PEB) enhances photoacid drift in the direction of the applied electric field, reduces bake time, and results in less undesired diffusion. Electric-field enhanced PEB can reduce PEB time by about 30%, and at the same time, improve the sharpness of 2D corners and increase the verticality of resist sidewalls. Electric-field-enhanced PEB also significantly improves the tolerance of over-exposure and provides better critical dimension control. It is estimated that the lateral acid diffusion length is reduced by about 50%. An apparatus for carrying out the aforementioned method is also provided.
    Type: Grant
    Filed: April 20, 2001
    Date of Patent: February 3, 2004
    Assignee: The Regents of the University of California
    Inventors: MoSong Cheng, Andrew R. Neureuther
  • Patent number: 6673363
    Abstract: Methods are provided for enhancing the permeability of skin or mucosal tissue to topical or transdermal application of local anesthetic agents. The methods entail the use of a base in order to increase the flux of the agent through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. The permeation enhancer can be an inorganic or organic base. Compositions and transdermal systems are also described.
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: January 6, 2004
    Assignee: Dermatrends, Inc.
    Inventors: Eric C. Luo, Nicole T. Gricenko, Tsung-Min Hsu
  • Patent number: 6649801
    Abstract: This invention provides an anionic borate ligand, and its synthesis. Zwitterionic complexes formed by the ligand and a metal, and Group 9 and 10 metals in particular, are described. Uses of the complexes in stoichiometric and catalytic reaction chemistry are also provided.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: November 18, 2003
    Assignee: California Institute of Technology
    Inventors: Jonas C. Peters, John C. Thomas, Connie Lu, Theodore A. Betley
  • Patent number: 6645524
    Abstract: Novel pharmaceutical dosage forms provide for pulsatile delivery of an antiarrhythmic agent that releases the drug in spaced apart “pulses.” The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads, granules, or particles or may comprise a single tablet with the first, second and optional third dosage units incorporated therein, or a “coated core” dosage form. Methods of treatment using the pharmaceutical dosage forms are provided as well.
    Type: Grant
    Filed: August 14, 2001
    Date of Patent: November 11, 2003
    Assignee: Pierce Management LLC
    Inventors: Kamal K. Midha, Mark Hirsh, Whe-Yong Lo
  • Patent number: 6645520
    Abstract: A method is provided for increasing the permeability of skin or mucosal tissue to transdermally administered nonsteroidal anti-inflammatory drugs (NSAIDs). The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the NSAID through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. Formulations and drug delivery systems for co-administering a hydroxide-releasing agent with an NSAID are provided as well.
    Type: Grant
    Filed: December 14, 2000
    Date of Patent: November 11, 2003
    Assignee: Dermatrends, Inc.
    Inventors: Tsung-Min Hsu, Eric C. Luo
  • Patent number: 6613926
    Abstract: Novel compounds are provided in the form of nucleoside pyrophosphate and triphosphate analogs. In these analogs, the pyrophosphate or triphosphate group is replaced with a moiety that is isosterically and electronically identical thereto, but is hydrolytically and enzymatically more stable. The compounds are useful as therapeutic agents, e.g., as antiviral agents, anticancer agents, metabolic moderators and the like. The invention also provides pharmaceutical compositions containing a compound of the invention as an active agent, and in addition provides methods of treating disease, including viral infections, cancer, bacterial infections, inflammatory and/or autoimmune diseases, and the like, by administering a compound of the invention to a patient in need of such treatment.
    Type: Grant
    Filed: November 1, 2000
    Date of Patent: September 2, 2003
    Assignee: SRI International
    Inventors: Jeffrey C. Bottaro, Robert J. Schmitt, Mark A. Petrie, Paul E. Penwell
  • Patent number: 6605115
    Abstract: Cardiovascular cell proliferation in a blood vessel subjected to trauma, such as angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 amino acid subunits, where at least 50% of the subunits are arginine, and the polymer contains at least six contiguous arginine subunits. Exemplary polymers for this purpose include arginine homopolymers 7 to 15 subunits in length.
    Type: Grant
    Filed: June 5, 2000
    Date of Patent: August 12, 2003
    Assignee: Board of Trustees of the Leland Stanford Junior University
    Inventors: John P. Cooke, Garrison C. Fathman, Jonathan B. Rothbard, Shiro Uemura, Robert C. Robbins, Murray H. Kown
  • Patent number: 6586000
    Abstract: A method is provided for increasing the permeability of skin or mucosal tissue to topically or transdermally administered pharmacologically or cosmeceutically active agents. The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the active agent through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. Topically applied formulations and drug delivery devices employing hydroxide-releasing agents as permeation enhancers are provided as well.
    Type: Grant
    Filed: December 14, 2000
    Date of Patent: July 1, 2003
    Assignee: Dermatrends, Inc.
    Inventors: Eric C. Luo, Eric C. Jacobson, Tsung-Min Hsu
  • Patent number: 6582724
    Abstract: A permeation enhancer composition is provided for increasing the permeability of skin or mucosal tissue to topically or transdermally administered pharmacologically or cosmeceutically active agents. The composition is comprised of a hydroxide-releasing agent and a lipophilic co-enhancer such as a fatty alcohol, a fatty ether, or a fatty acid ester, including fatty acid esters of polyols such as propylene glycol and glycerol. Also provided are pharmaceutical formulations containing a therapeutically effective amount of an active agent in addition to the aforementioned enhancer composition, methods for administering active agents topically or transdermally with enhanced permeation, and drug delivery systems for application to an individual's skin or mucosal tissue, wherein the systems are formulated so as to contain an active agent to be administered and an effective permeation enhancing amount of an enhancer composition of the invention.
    Type: Grant
    Filed: October 4, 2001
    Date of Patent: June 24, 2003
    Assignee: Dermatrends, Inc.
    Inventors: Tsung-Min Hsu, Eric C. Jacobson, Rose C. LoBello, Eric C. Luo
  • Patent number: 6565879
    Abstract: A method is provided for increasing the permeability of skin or mucosal tissue to a topically or transdermally administered pharmacologically or cosmeceutically active peptide, polypeptide or protein. The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the peptide, polypeptide or protein through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. Formulations and drug delivery devices employing hydroxide-releasing agents as permeation enhancers are provided as well.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: May 20, 2003
    Assignee: Dermatrends, Inc.
    Inventors: Eric C. Luo, Eric C. Jacobson, Tsung-Min Hsu
  • Patent number: 6562369
    Abstract: A method is provided for increasing the permeability of skin or mucosal tissue to transdermally administered androgenic drugs. The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the androgenic drug through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. Formulations and drug delivery systems for co-administering a hydroxide-releasing agent with an androgenic drug are provided as well.
    Type: Grant
    Filed: December 14, 2000
    Date of Patent: May 13, 2003
    Assignee: Dermatrends, Inc.
    Inventors: Eric C. Luo, Tsung-Min Hsu
  • Patent number: 6562368
    Abstract: A method is provided for increasing the permeability of skin or mucosal tissue to transdermally administered oxybutynin. The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the drug through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. Formulations, drug delivery systems and methods of treatment are provided as well.
    Type: Grant
    Filed: December 14, 2000
    Date of Patent: May 13, 2003
    Assignee: Dermatrends, Inc.
    Inventors: Tsung-Min Hsu, Eric C. Luo
  • Patent number: 6562370
    Abstract: A method is provided for increasing the permeability of skin or mucosal tissue to transdermally administered steroid drugs. The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the drug through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. Formulations and drug delivery systems for co-administering a hydroxide-releasing agent with a steroid drug are provided as well. Optimally, the steroid drugs are a combination of an estrogen and progestin that may be administered in female hormone replacement therapy, to provide female contraception, and the like.
    Type: Grant
    Filed: December 14, 2000
    Date of Patent: May 13, 2003
    Assignee: Dermatrends, Inc.
    Inventors: Eric C. Luo, Tsung-Min Hsu